| Ytd | -6.96% | |
| 1y | -6.96% |
| Open | 1.55 | Prev Close | 1.59 | Low | 1.42 | High | 1.57 | Mkt Cap | 218.42M |
| Vol | 8.77M | Avg Vol | 18.92M | EPS | -1.13 | P/E | N/A | Forward P/E | -0.55 |
| Beta | 0.63 | Short Ratio | 1.26 | Inst. Own | 35.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 0.73 | 200-d Avg | 0.90 | 1yr Est | 24.80 |
OTLK News
Outlook Therapeutics shares rose after the FDA accepted its resubmitted LYTENAVA BLA and set a July
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the stand
Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ra
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and
Outlook Therapeutics Inc. shares are trading higher Tuesday after the FDA granted its appeal in the
Wall Street analysts changed ratings on top stocks. Check out the complete list on Benzinga's an
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.16) per share which missed the a
Effective May 12, 2026, Outlook Therapeutics canceled its at-the-market sales agreement, dated as of
On May 13, 2026, Outlook Therapeutics, Inc. (the "Company") entered into an At The Market Of
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the stan
Outlook Therapeutics files FDA dispute on ONS-5010 after CRL citing effectiveness concerns; meeting
U.S. stocks fall with Dow down 0.46%, S&P 500 down 0.52%, NASDAQ down 0.89%. Energy up 2.5%, com
US stocks lower on Tuesday as Dow falls over 350 points while NASDAQ and S&P 500 also decline. E
PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the stand
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the stan
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the stan
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the stan
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.22) per share which missed the a
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the stand
U.S. stock futures up, Apple reduces Vision Pro production, TSMC gets U.S. export license, VS Media